GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004873218 | Prostate | BPH | gland development | 122/3107 | 436/18723 | 1.13e-09 | 5.01e-08 | 122 |
GO:004362018 | Prostate | BPH | regulation of DNA-templated transcription in response to stress | 28/3107 | 53/18723 | 1.57e-09 | 6.70e-08 | 28 |
GO:000756816 | Prostate | BPH | aging | 100/3107 | 339/18723 | 1.77e-09 | 7.44e-08 | 100 |
GO:003629317 | Prostate | BPH | response to decreased oxygen levels | 96/3107 | 322/18723 | 2.03e-09 | 8.26e-08 | 96 |
GO:000166617 | Prostate | BPH | response to hypoxia | 92/3107 | 307/18723 | 3.29e-09 | 1.27e-07 | 92 |
GO:004578518 | Prostate | BPH | positive regulation of cell adhesion | 120/3107 | 437/18723 | 5.22e-09 | 1.90e-07 | 120 |
GO:000170110 | Prostate | BPH | in utero embryonic development | 104/3107 | 367/18723 | 9.17e-09 | 3.10e-07 | 104 |
GO:003410118 | Prostate | BPH | erythrocyte homeostasis | 48/3107 | 129/18723 | 1.34e-08 | 4.26e-07 | 48 |
GO:000226218 | Prostate | BPH | myeloid cell homeostasis | 54/3107 | 157/18723 | 4.02e-08 | 1.12e-06 | 54 |
GO:004361818 | Prostate | BPH | regulation of transcription from RNA polymerase II promoter in response to stress | 24/3107 | 47/18723 | 5.48e-08 | 1.50e-06 | 24 |
GO:003021818 | Prostate | BPH | erythrocyte differentiation | 44/3107 | 120/18723 | 8.72e-08 | 2.16e-06 | 44 |
GO:000189010 | Prostate | BPH | placenta development | 50/3107 | 144/18723 | 8.97e-08 | 2.20e-06 | 50 |
GO:00715597 | Prostate | BPH | response to transforming growth factor beta | 76/3107 | 256/18723 | 1.14e-07 | 2.73e-06 | 76 |
GO:004887218 | Prostate | BPH | homeostasis of number of cells | 79/3107 | 272/18723 | 1.79e-07 | 3.99e-06 | 79 |
GO:003052216 | Prostate | BPH | intracellular receptor signaling pathway | 77/3107 | 265/18723 | 2.49e-07 | 5.42e-06 | 77 |
GO:007145315 | Prostate | BPH | cellular response to oxygen levels | 56/3107 | 177/18723 | 5.50e-07 | 1.09e-05 | 56 |
GO:00075697 | Prostate | BPH | cell aging | 45/3107 | 132/18723 | 7.00e-07 | 1.35e-05 | 45 |
GO:00715607 | Prostate | BPH | cellular response to transforming growth factor beta stimulus | 72/3107 | 250/18723 | 8.71e-07 | 1.61e-05 | 72 |
GO:000189210 | Prostate | BPH | embryonic placenta development | 32/3107 | 82/18723 | 9.93e-07 | 1.80e-05 | 32 |
GO:003629415 | Prostate | BPH | cellular response to decreased oxygen levels | 51/3107 | 161/18723 | 1.66e-06 | 2.79e-05 | 51 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CIT | SNV | Missense_Mutation | rs779515686 | c.4130N>T | p.Pro1377Leu | p.P1377L | O14578 | protein_coding | deleterious(0) | benign(0.248) | TCGA-A2-A0EW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
CIT | SNV | Missense_Mutation | | c.5132C>T | p.Ser1711Phe | p.S1711F | O14578 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
CIT | SNV | Missense_Mutation | novel | c.2482N>A | p.Glu828Lys | p.E828K | O14578 | protein_coding | deleterious(0.04) | possibly_damaging(0.628) | TCGA-A2-A25C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CIT | SNV | Missense_Mutation | | c.3097G>T | p.Val1033Leu | p.V1033L | O14578 | protein_coding | tolerated(0.08) | probably_damaging(0.978) | TCGA-A8-A076-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
CIT | SNV | Missense_Mutation | rs747447396 | c.2839C>T | p.Arg947Cys | p.R947C | O14578 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CIT | SNV | Missense_Mutation | rs747447396 | c.2839N>T | p.Arg947Cys | p.R947C | O14578 | protein_coding | deleterious(0.02) | possibly_damaging(0.446) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CIT | SNV | Missense_Mutation | | c.242N>T | p.Ser81Phe | p.S81F | O14578 | protein_coding | deleterious(0.02) | benign(0.17) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
CIT | SNV | Missense_Mutation | novel | c.637N>T | p.His213Tyr | p.H213Y | O14578 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
CIT | SNV | Missense_Mutation | rs368981957 | c.5590N>A | p.Asp1864Asn | p.D1864N | O14578 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CIT | SNV | Missense_Mutation | novel | c.1771N>A | p.Glu591Lys | p.E591K | O14578 | protein_coding | tolerated(0.31) | benign(0.019) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |